

## Genetics of Neonatal Diabetes Mellitus

Sepideh Shahkarami<sup>1</sup> and Nima Rezaei<sup>1,2</sup>

<sup>1</sup> Research Center for Immunodeficiencies, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

<sup>2</sup> Department of Immunology, Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Although exact etiology of diabetes mellitus is still unknown, it seems that it follows a polygenic trait, while genetic and environmental factors could influence its present in most cases. However, monogenic forms of disease have also been described, which usually presented either during neonate and early infancy period, named as neonatal diabetes mellitus (NDM), or during childhood and adolescence, named as maturity onset diabetes of the young (MODY). MODY seems to be more common than NDM (1-3).

According to different gene mutations, eleven different MODY types have already been described by now, while MODY type 2 due to mutation of the *GCK* gene seems to be the most common form. Mutations in the *ABCC8* gene could cause permanent or transient NDM, while mutations of the *KCNJ11* gene could lead to permanent NDM. Several other genes, including *PLAGL1*, *ZFP57*, *INS*, *EIF2AK3*, *FOXP3*, *PDX1*, *PTF1A*, *NEUROD1*, *NEUROG3*, *RFX6*, *IER3IP1*, *HNF1B*, *GLIS3*, *PAX6*, *WFS1*, *SLC19A2*, and *SLC2A2* have also been reported in association with NDM (2,4). Since mutations of these genes would initiate particular clinical phenotypes and complications and therefore might require a specific therapeutic protocol, identification of the NDM-causing genes seems essential for efficient and specific treatment.

Fanconi-Bickel syndrome (FBS, OMIM#227810) is a rare monogenic disorder with autosomal recessive pattern of inheritance, due to homozygous or compound heterozygous mutations of the *Soluble Carrier Family 2 (Facilitated Glucose Transporter), Member 2 (SLC2A2, OMIM\*138160)* gene, mapped on chromosome 3q26.1-26.3, which encodes glucose transporter protein 2 (GLUT2), expressing in pancreas, liver, intestine, and renal tubular cells (5,6).

Patients with FBS usually manifest hepatomegaly due to glycogen accumulation, proximal tubular dysfunction results in inappropriate urinary losses of mineral elements, repeated pneumonia, moon-shaped

face, short stature, hypophosphatemic rickets, and glucose intolerance which may be due to a NDM and impaired galactose tolerance (6,7). It should be noted that a variety of manifestations, including neurodevelopmental disability, exocrine pancreatic insufficiency, thyroid dysfunction, kidney structural or functional defects, liver dysfunction, skeletal abnormalities, visual impairment, deafness, and megaloblastic anemia have been reported in association with different genetic mutations in NDM (4).

In a recently interesting published paper in the *Acta Medica Iranica*, entitled "Transient neonatal diabetes as a presentation of Fanconi-Bickel syndrome", clinical features of a female case with diagnosis of FBS have been described. The patient had a short stature, hepatomegaly, and hypophosphatemic rickets, while history of diabetic ketoacidosis and transient NDM are well-noted. The diagnosis of FBS was made considering the clinical phenotype and homozygous mutation in the intronic region of the *SLC2A2* gene (8). Molecular genetic studies over the past years have been resulted in identifying more than 30 different mutations (missense, nonsense, frame shift, and splice-sites), scattering through all of coding exons in the gene *SLC2A2* among the patients with FBS (9). Interestingly, there are several reports of disease-causing mutations in the intronic regions of the *SLC2A2* gene, such as c.963+1G>A in the mentioned article, which is predicted to be causative because of its aberrant effect on the splicing site (7,8). To strengthen the pathogenic role of such mutations, protein analysis or carrier frequencies detection of the mutations in non-related normal subjects is needed to see if they really disrupt protein sequence or not. However, clinical suspicious and known mutations could be useful for making definite diagnosis.

It is noteworthy that the most of reported mutations were novel, which makes the molecular diagnosis laborious (6,10-18). As a result, preparing genetic profile in the FBS patients could be helpful not only for

**Corresponding Author:** Nima Rezaei

Children's Medical Center Hospital, Dr. Qarib St, Keshavarz Blvd, Tehran 14194, Iran  
Tel: +9821 6692 9234, Fax: +9821 6692 9235, E-mail: rezaei\_nima@tums.ac.ir

confirming the diagnosis as a diagnostic tool, but also for predicting the clinical phenotypes as a prognostic tool. It shows the value of mutation detection in the clinical settings. Therefore, besides the importance of clinical and laboratory findings, significance of genetic analysis should never be underestimated.

### References

1. Vaxillaire M, Bonnefond A, Froguel P. The lessons of early-onset monogenic diabetes for the understanding of diabetes pathogenesis. *Best Pract Res Clin Endocrinol Metab.* 2012;26(2):171-87.
2. Greeley SA, Naylor RN, Philipson LH, Bell GI. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. *Curr Diab Rep.* 2011;11(6):519-32.
3. Steck AK, Winter WE. Review on monogenic diabetes. *Curr Opin Endocrinol Diabetes Obes.* 2011;18(4):252-8.
4. Greeley SA, Naylor RN, Philipson LH, Bell GI. Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. *Curr Diab Rep.* 2011;11:519-32. doi: 10.1007/s11892-011-0234-7.
5. Santer R, Schneppenheim R, Dombrowski A, Götze H, Steinmann B, Schaub J.. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. *Nat Genet* 1997;17:324–326.
6. Santer R, Groth S, Kinner M, Dombrowski A, Berry GT, Brodehl J, Leonard JV, Moses S, Norgren S, Skovby F, Schneppenheim R, Steinmann B, Schaub J. The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. *Hum Genet* 2002;110:21–29.
7. Sansbury FH, Flanagan SE, Houghton JA, Shuixian Shen FL, Al-Senani AM, Habeb AM, Abdullah M, Kariminejad A, Ellard S, Hattersley AT. SLC2A2 mutations can cause neonatal diabetes, suggesting GLUT2 may have a role in human insulin secretion. *Diabetologia* 2012;55:2381-5.
8. Setoodeh A, Rabbani A. Transient neonatal diabetes as a presentation of Fanconi- Bickel syndrome. *Acta Med Iran* 2012;50:836-8.
9. Von Mühlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. *N Engl J Med* 1995 14;333:704-8.
10. Roy M, Bose K, Paul DK, Anand P. Hypophosphatemic rickets: presenting features of fanconi-bickel syndrome. *Case Report Pathol* 2011;2011:314696.
11. Saltik-Temizel IN, Coşkun T, Yüce A, Koçak N. Fanconi-Bickel syndrome in three Turkish patients with different homozygous mutations. *Turk J Pediatr* 2005;47:167-9.
12. Al-Haggag M, Sakamoto O, Shaltout A, Al-Hawari A, Wahba Y, Abdel-Hadi D. Mutation analysis of the GLUT2 gene in three unrelated Egyptian families with Fanconi-Bickel syndrome: revisited gene atlas for renumbering. *Clin Exp Nephrol* 2012;16:604-10.
13. Karamizadeh Z, Saki F, Imanieh MH, Zahmatkeshan M, Faradae M. A new mutation of Fanconi-Bickel syndrome with liver failure and pseudotumour cerebri. *J Genet* 2012;91:359-61.
14. Yoo HW, Shin YL, Seo EJ, Kim GH. Identification of a novel mutation in the GLUT2 gene in a patient with Fanconi-Bickel syndrome presenting with neonatal diabetes mellitus and galactosaemia. *Eur J Pediatr* 2002;161:351-3.
15. Ozer EA, Aksu N, Uclar E, Erdogan H, Bakiler AR, Tsuda M, Kitasawa E, Coker M, Ozer E. No mutation in the SLC2A2 (GLUT2) gene in a Turkish infant with Fanconi-Bickel syndrome. *Pediatr Nephrol* 2003;18:397-8.
16. Peduto A, Spada M, Alluto A, La Dolcetta M, Ponzzone A, Santer R. A novel mutation in the GLUT2 gene in a patient with Fanconi-Bickel syndrome detected by neonatal screening for galactosaemia. *J Inherit Metab Dis* 2004;27:279-80.
17. Simşek E, Savaş-Erdeve S, Sakamoto O, Doğancı T, Dallar Y. A novel mutation of the GLUT2 gene in a Turkish patient with Fanconi-Bickel syndrome. *Turk J Pediatr* 2009;51:166-8.
18. Gopalakrishnan A, Kumar M, Krishnamurthy S, Sakamoto O, Srinivasan S. Fanconi-Bickel syndrome in a 3-year-old Indian boy with a novel mutation in the GLUT2 gene. *Clin Exp Nephrol* 2011;15:745-8.